Weight gain, during and after the menopause is common. Contributing factors include ethnicity, reduced physical activity reduced lean mass, reduced resting metabolic rate and treatment with certain drugs, e.g. steroids, insulin, glitazones. Excess body weight increases the risk of medical conditions including type 2 diabetes, hypertension, osteoarthritis, certain cancers and is associated with increased mortality. This review examines pharmacological approaches to promote weight loss. Pharmacological therapy should be considered as an adjunct to diet and lifestyle changes. The licensed drugs orlistat, sibutramine and rimonabant are discussed. Obesity increases the risk of type 2 diabetes. Thus, the effects of metformin and exenatide are examined.
National Task Force on the Prevention and Treatment of Obesity.Overweight, obesity and health risk. Arch Intern Med2000; 160: 898-904
2.
AdamsKF, SchatzkinA, HarrisTBOverweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med2006; 355: 763-78
3.
WillettWC, MansonJE, StampferMJWeight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA1995; 273: 461-5
4.
MansonJE, WilletWC, StampferMJBody weight and mortality among women. N Engl J Med1995; 333: 677-85
5.
YusufS, HawkenS, OunpuuSObesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case control study. Lancet2005; 366: 1640-9
6.
ZhangX, XiaoShu, YangGAbdominal adiposity and mortality in Chinese women. Arch Intern Med2007; 167: 886-92
7.
EliassenAH, ColditzGA, RosnerBAdult weight change and risk of postmenopausal breast cancer. JAMA2006; 296: 193-201
8.
ReevesGK, PirieK, BeralVMillion Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ2007; 335: 1134
9.
ArcieroPJ, GoranMI, PoehlmanET. Resting metabolic rate is lower in women than in men. J Appl Physiol1993; 75: 2514-20
10.
PoehlmanE, GoranM, GardnerADeterminants of decline in resting metabolic rate in aging females. Am J Physiol1993; 264: E450-5
11.
ChiyokoU, JunO, JunY, YumiS, MitsuruH. Basic metabolic rates and its determinants in postmenopausal women. The Japanese Society of Physical Fitness and Sport Medicine.2003; 52: 189-198
12.
Van PeltR, JonesP, DavyKRegular exercise and the age related decline in resting metabolic rate in women. J Clin Endocrinol Metab1997; 82: 3208-12
13.
FernandezJ, ShriverM, BeasleyTAssociation of African Genetic Admixture with resting metabolic rate and obesity among women. Obes Res2003; 11: 904-11
14.
KongnyyuyE, NormanRJ, FlightIHK, ReesMCP. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev2007; (2) CD001018
15.
WilliamsonDF, PamukE, ThunM, FlandersD, ByersT, HeathC. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol1995; 141: 1128-41
16.
FurbergAS, ThuneI. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer2003; 104: 669-76
17.
LittmanAJ, VoigtLF, BeresfordSA, WeissNS. Recreational physical activity and endometrial cancer risk. Am J Epidemiol2001; 154: 924-33
18.
MoradiT, WeiderpassE, SignorelloLBPhysical activity and postmenopausal endometrial cancer risk (Sweden). Cancer Causes Control2000; 11: 829-37
19.
SvendsenOL, HassagerC, ChristiansenC. Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med1993; 95: 131-40
20.
SnowV, BarryP, FittermanN, QaseemA, WeissK. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med2005; 142: 525-31
21.
YanovskiSZ, YanovskiJA. Obesity. N Engl J Med2002; 346: 591-602
22.
KnowlerWC, Barrett-ConnorE, FowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or met formin. N Engl J Med2002; 346: 393-403
23.
DouketisJD, MacieC, ThabaneL, WilliamsonDF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond)2005; 29: 1153-67
24.
LiZ, MaglioneM, TuWMeta-analysis: pharmacologic treatment of obesity. Ann Intern Med2005; 142: 532-46
25.
TorgersonJS, HauptmanJ, BoldrinMN, SjostromL. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care2004; 27: 155-61
26.
MilesJM, LeiterL, HollanderPEffect of orlistat in over weight and obese patients with type 2 diabetes treated with metformin. Diabetes Care2002; 25: 1123-8
27.
KelleyDE, BrayGA, Pi-SunyerFXClinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care1998; 21: 1288-94
28.
DavidsonMH, HauptmanJ, DiGirolamoMWeight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA1999; 281: 235-42
29.
TonstadS, PomettaD, ErkelensDWThe effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol1994; 46: 405-10
30.
ReitsmaJB, Castro CabezasM, de BruinTW, ErkelensDW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism1994; 43: 293-8
31.
PadwalR, LiSK, LauDC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev2004; (3) : CD004094
32.
JamesWP, AstrupA, FinerNEffect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet2000; 356: 2119-25
33.
Mathus-VliegenEM. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr2005; 59: S31-8
34.
VettorR, SerraR, FabrisREffect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care2005; 28: 942-9
35.
Serrano-RiosM, MechiondaN, Moreno CarreteroERole of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med2002; 19: 119-24
36.
KimSH, LeeYM, JeeSH, NamCM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res2003; 11: 1116-23
37.
WaddenTA, BerkowitzRI, WombleLGEffects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res2000; 8: 431
38.
KayaA, AydinN, TopseverPEfficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother2004; 58: 582-7
39.
CurioniC, AndreC. Rimonabant for overweight or obesity. Cochrane Database Syst Rev2006; 4: CD006162
40.
Pi-SunyerFX, AronneLJ, HeshmatiHMEffect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardio-metabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA2006; 295: 761-5
41.
Van GaalLF, RissanenAM, ScheenAJEffects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet2005; 365: 1389-97
42.
DaviesKM, HeaneyRP, ReckerRRCalcium intake and body weight. J Clin Endocrinol Metab2000; 85: 4635-8
43.
ShapsesSA, HeshkaS, HeymsfieldSB. Effect of calcium supplementation on weight and fat loss in women. J Clin Endocrinol Metab2004; 89: 632-7
44.
ReidIR, HomeA, MasonBEffects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab2005; 90: 3824-9
45.
VahlN, JorgensenJO, SkjaerbeakCAbdominal obesity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol1997; 272: E1108-16
46.
FrancoC, BrandbergJ, LonnLGrowth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12 month placebo controlled trial. J Clin Endocrinol Metab2005; 90: 1436-74
47.
KnowlerWC, Barrett-ConnorE, FowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002; 346: 393-403
48.
DeFronzoRA, RatnerRE, HanJEffects of exenatide (exendin-4) on glycemie control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care2005; 28: 1092-100
49.
BuchwaldH, AvidorY, BraunwaldEBariatric surgery: a systematic review and meta-analysis. JAMA2004; 292: 1724-37
50.
SjöströmL, NarbroK, SjöströmCDEffects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med2007; 357: 741-52
